After chemotherapy disease progresses in some of the patients with advanced BRAF V600E mutant non-small cell lung cancer. The BRAF inhibitor dabrafenib was found to have significant anti-tumour activity in such patients. Phase II data presented at the ESMO 2014 Congress in Madrid, Spain revealed the results.
"Reports of lung cancers bearing mutations in BRAF have generated considerable interest because these mutations may be associated with increased sensitivity to BRAF tyrosine-kinase inhibiting ...
After chemotherapy disease progresses in some of the patients with advanced BRAF V600E mutant non-small cell lung cancer. The BRAF inhibitor dabrafenib was found to have significant anti-tumour activity in such patients. Phase II data presented at the ESMO 2014 Congress in Madrid, Spain revealed the results.
"Reports of lung cancers bearing mutations in BRAF have generated considerable interest because these mutations may be associated with increased sensitivity to BRAF tyrosine-kinase inhibiting ...